{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.75","value":"18.5"},{"groupId":"OG001","spread":"6.57","value":"21.2"},{"groupId":"OG002","spread":"2.56","value":"21.5"}]}],"title":"Screening, n=16, 14, 10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.57","value":"19.2"},{"groupId":"OG001","spread":"7.74","value":"2.12"},{"groupId":"OG002","spread":"4.76","value":"21.7"}]}],"title":"Day 1 , n=21, 21, 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.74","value":"19.1"},{"groupId":"OG001","spread":"3.93","value":"20.4"},{"groupId":"OG002","spread":"7.63","value":"25.1"}]}],"title":"Week 1, n=24, 25, 14"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.56","value":"19.4"},{"groupId":"OG001","spread":"6.85","value":"21.8"},{"groupId":"OG002","spread":"10.83","value":"25.2"}]}],"title":"Week 2, n=22, 24, 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.73","value":"18.8"},{"groupId":"OG001","spread":"4.40","value":"21.2"},{"groupId":"OG002","spread":"6.09","value":"24.0"}]}],"title":"Week 3, n=24, 23, 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.59","value":"19.0"},{"groupId":"OG001","spread":"3.82","value":"20.9"},{"groupId":"OG002","spread":"6.37","value":"24.3"}]}],"title":"Week 4, n=23, 23, 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.13","value":"18.9"},{"groupId":"OG001","spread":"3.19","value":"19.8"},{"groupId":"OG002","spread":"12.91","value":"26.9"}]}],"title":"Week 5, n=23, 23, 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.30","value":"19.3"},{"groupId":"OG001","spread":"4.11","value":"20.6"},{"groupId":"OG002","spread":"4.92","value":"23.3"}]}],"title":"Week 6, n=23, 22, 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.99","value":"18.8"},{"groupId":"OG001","spread":"4.46","value":"20.1"},{"groupId":"OG002","spread":"4.60","value":"22.4"}]}],"title":"Week 7, n=22, 25, 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.32","value":"19.2"},{"groupId":"OG001","spread":"6.23","value":"23.4"},{"groupId":"OG002","spread":"1.79","value":"22.0"}]}],"title":"Week 8, n=19, 19, 10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.96","value":"19.5"},{"groupId":"OG001","spread":"3.95","value":"22.0"},{"groupId":"OG002","spread":"4.48","value":"22.5"}]}],"title":"Week 9, n=17, 16, 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.27","value":"18.7"},{"groupId":"OG001","spread":"3.83","value":"22.8"},{"groupId":"OG002","spread":"6.83","value":"23.3"}]}],"title":"Week 10, n=16, 13, 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.28","value":"18.9"},{"groupId":"OG001","spread":"3.11","value":"22.8"},{"groupId":"OG002","spread":"5.29","value":"22.2"}]}],"title":"Week 11, n=15, 13, 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.90","value":"18.6"},{"groupId":"OG001","spread":"3.76","value":"22.2"},{"groupId":"OG002","spread":"4.98","value":"23.6"}]}],"title":"Week 12, n=17, 16, 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.56","value":"19.3"},{"groupId":"OG001","spread":"7.68","value":"23.4"},{"groupId":"OG002","spread":"2.62","value":"21.0"}]}],"title":"Week 13, n=11, 13, 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.98","value":"18.7"},{"groupId":"OG001","spread":"5.49","value":"19.9"},{"groupId":"OG002","spread":"4.86","value":"23.4"}]}],"title":"Week 14, n=13, 11, 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.76","value":"18.7"},{"groupId":"OG001","spread":"2.53","value":"21.1"},{"groupId":"OG002","spread":"8.76","value":"24.4"}]}],"title":"Week 15, n=12, 13, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.26","value":"18.6"},{"groupId":"OG001","spread":"7.97","value":"22.9"},{"groupId":"OG002","spread":"6.88","value":"24.3"}]}],"title":"Week 16, n=16, 14, 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.08","value":"19.0"},{"groupId":"OG001","spread":"6.45","value":"22.4"},{"groupId":"OG002","spread":"9.65","value":"25.2"}]}],"title":"Week 17, n=13, 10, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.79","value":"19.1"},{"groupId":"OG001","spread":"4.53","value":"22.0"},{"groupId":"OG002","spread":"10.52","value":"29.0"}]}],"title":"Week 18, n=16, 12, 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.49","value":"18.1"},{"groupId":"OG001","spread":"19.33","value":"24.5"},{"groupId":"OG002","spread":"6.45","value":"24.0"}]}],"title":"Week 19, n=14, 13, 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.94","value":"17.4"},{"groupId":"OG001","spread":"3.52","value":"20.9"},{"groupId":"OG002","spread":"16.77","value":"33.00"}]}],"title":"Week 20, n=13, 13, 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.40","value":"18.8"},{"groupId":"OG001","spread":"3.55","value":"20.2"},{"groupId":"OG002","spread":"10.58","value":"28.0"}]}],"title":"Week 21, n=4, 10, 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.94","value":"19.7"},{"groupId":"OG001","spread":"2.79","value":"19.1"},{"groupId":"OG002","spread":"4.90","value":"26.0"}]}],"title":"Week 22, n=11, 7, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.72","value":"20.4"},{"groupId":"OG001","spread":"3.24","value":"21.1"},{"groupId":"OG002","spread":"5.13","value":"23.7"}]}],"title":"Week 23, n=8, 7, 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.03","value":"19.1"},{"groupId":"OG001","spread":"3.11","value":"20.2"},{"groupId":"OG002","spread":"5.47","value":"23.8"}]}],"title":"Week 24, n=22, 23, 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.60","value":"18.8"},{"groupId":"OG001","spread":"3.41","value":"20.0"},{"groupId":"OG002","spread":"10.39","value":"26.0"}]}],"title":"FU Week 1, n=6, 6, 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.63","value":"18.7"},{"groupId":"OG001","spread":"4.15","value":"20.8"},{"groupId":"OG002","spread":"4.02","value":"22.2"}]}],"title":"FU Week 2, n=6, 5, 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.67","value":"19.0"},{"groupId":"OG001","spread":"4.16","value":"23.0"},{"groupId":"OG002","spread":"5.50","value":"24.8"}]}],"title":"FU Week 3, n=6, 4, 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.97","value":"19.4"},{"groupId":"OG001","spread":"1.86","value":"20.8"},{"groupId":"OG002","spread":"3.74","value":"21.0"}]}],"title":"FU Week 4, n=10, 12, 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.78","value":"23.0"},{"groupId":"OG001","spread":"13.00","value":"27.7"},{"groupId":"OG002","spread":"11.54","value":"27.7"}]}],"title":"MPB, n=24, 26, 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"description":"Respiratory rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline visit included any scheduled and unscheduled post-Baseline assessment. Participants randomized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.","dispersionType":"Standard Deviation","groups":[{"description":"All participants aged between 12 and 17 years and completing Part 2 of the study received an Open-Label treatment of eltrombopag administered as a tablet in Part 2/3. Participants who received placebo in Part 2 received 24 weeks of treatment of eltrombopag starting at 37.5 mg QD up to Week 31 of the study. Participants who received 7 weeks of eltrombopag treatment in Part 2 received an additional 17 weeks of treatment to complete a total of 24 weeks continuing at the same dosage at the end of Part 2. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.","id":"OG000","title":"Part 2/3 (Eltrombopag Period) Cohort 1"},{"description":"All participants aged between 6 and 11 years and completing Part 2 of the study received an Open -Label treatment of eltrombopag administered as a tablet in Part 2/3. Participants with difficulty swallowing a tablet in Part 2 were administered eltrombopag as a dry powder for oral suspension in Part 2/3. Participants who received placebo in Part 2 received 24 weeks of treatment of eltrombopag based on body weight up to Week 31 of the study. Participants with a body weight of \\<=27 kg received 25 mg QD and participants with a body weight of \\>=27 kg QD received 50 mg QD. Participants who received 7 weeks of eltrombopag treatment in Part 2 received an additional 17 weeks of treatment to complete a total of 24 weeks continuing at the same dosage at the end of Part 2. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.","id":"OG001","title":"Part 2/3 (Eltrombopag Period) Cohort 2"},{"description":"All participants aged between 1 and 5 years and completing Part 2 of the study received an Open-Label treatment of eltrombopag administered as a dry powder for oral suspension in Part 2/3. Participants who received placebo in Part 2 received 24 weeks of treatment of eltrombopag up to Week 31 of the study at 1.5 mg/kg QD. Participants of East Asian ancestry received 0.8 mg/kg/day. Participants who received 7 weeks of eltrombopag treatment in Part 2 received an additional 17 weeks of treatment to complete a total of 24 weeks continuing at the same dosage at the end of Part 2. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.","id":"OG002","title":"Part 2/3 (Eltrombopag Period) Cohort 3"}],"paramType":"MEAN","populationDescription":"Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the Safety Population.","reportingStatus":"POSTED","timeFrame":"From Week 1 to Follow-up Week 4 of Part 2/3 up to Study Week 35","title":"Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3","type":"SECONDARY","unitOfMeasure":"Breaths per minute"}